百济神州一季度亏损大幅收窄 国内BTK抑制剂销售加速、PD-1销售减速

每日经济新闻
07 May

5月7日晚间,百济神州(SH688235,股价238.50元,市值3345亿元)发布2025年一季报。公司一季度产品收入为79.85亿元,同比上升49.9%;营业总收入为80.48亿元,同比上升50.2%;归属于母公司所有者的净利润为-0.95亿元,亏损同比大幅收窄。作为国内创新药龙头企业,百济神州目前有3款主要自研产品,分别为BTK抑制剂泽布替尼(商品名:百悦泽)、PD-1单抗替雷利珠单抗(商品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10